Friday, September 24, 2021
Tags Medical Research

Tag: Medical Research

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J., Sept. 20, 2021 (SEND2PRESS NEWSWIRE) -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT.

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

AUSTIN, Texas and CAMBRIDGE, U.K., July 21, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital.

Mouth bacteria could make stronger vaccines

HAMPTON, N.J., June 3, 2021 (SEND2PRESS NEWSWIRE) -- Three researchers have published a groundbreaking paper on the importance of oral bacteria in the fight against infectious diseases like influenza, HIV, and COVID-19, Gingivax LLC announced today.

The Pap Corps Donates $2 Million to Sylvester Comprehensive Cancer Center

DEERIELD BEACH, Fla., May 21, 2021 (SEND2PRESS NEWSWIRE) -- Overcoming the numerous obstacles imposed by the pandemic, The Pap Corps Champions for Cancer Research displayed their indomitable spirit during their May Presidents Zoom meeting when they announced a $2 million donation to Sylvester Comprehensive Cancer Center.

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas, March 31, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

C Diff Foundation Releases ‘C diff and You’ App for Patients, Families, and Caregivers

TAMPA, Fla., March 16, 2021 (SEND2PRESS NEWSWIRE) -- C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with...

AUSTIN, Texas and LONDON, England, Feb. 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London.

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb. 9, 2021 (SEND2PRESS NEWSWIRE) -- Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of...

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 4, 2021 (SEND2PRESS NEWSWIRE) -- Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

AUSTIN, Texas and BASEL, Switzerland, Jan. 27, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.

Drink HRW Reports on Start of Large-Scale Randomized Controlled Trial and Preliminary Findings from Pilot Trial on the Reduction in Complications...

COQUITLAM, BC, Canada, Jan. 19, 2021 (SEND2PRESS NEWSWIRE) -- Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results.

C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers

TAMPA, Fla., Jan. 13, 2021 (SEND2PRESS NEWSWIRE) -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.
C Diff Foundation Clinical Trials

C Diff Foundation Assures Patients that C. diff. Clinical Trials Continue Moving Forward Safely

TAMPA, Fla. /Florida Newswire/ -- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act...

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.
2020 International C DIFF EXPO

2020 International C DIFF (Clostridioides difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. /Florida Newswire/ -- The C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif., Oct. 26, 2020 (SEND2PRESS NEWSWIRE) -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week.

Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant

VENTURA, Calif., Oct. 7, 2020 (SEND2PRESS NEWSWIRE) -- Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

FEATURED NEWS

NATIONAL NEWS